Marquette University

e-Publications@Marquette
Biomedical Sciences Faculty Research and
Publications

Biomedical Sciences, Department of

2-9-2022

Complexes of Ghrelin GHS-R1a, GHS-R1b, and Dopamine D1
Receptors Localized in the Ventral Tegmental Area as Main
Mediators of the Dopaminergic Effects of Ghrelin
Gemma Navarro
William Rea
César Quiroz
Estefanía Moreno
Devan Gomez

See next page for additional authors

Follow this and additional works at: https://epublications.marquette.edu/biomedsci_fac
Part of the Neurosciences Commons

Authors
Gemma Navarro, William Rea, César Quiroz, Estefanía Moreno, Devan Gomez, Cody J. Wenthur, Vicent
Casadó, Lorenzo Leggio, Matthew C. Hearing, and Sergi Ferré

940 • The Journal of Neuroscience, February 9, 2022 • 42(6):940-953

Cellular/Molecular

Complexes of Ghrelin GHS-Rla, GHS-Rlb, and Dopamine
D1 Receptors Localized in the Ventral Tegmental Area as
Main Mediators of the Dopaminergic Effects of Ghrelin
Gemma Navarro,' William Rea,2 Cesar Quiroz,2 Estefania Moreno,3 Devan Gomez,4 Cody
Vicent Casado, 3 Lorenzo Leggio, 6 Matthew C. Hearing,4 and Sergi Ferre2

J. Wenthur, 5

1Department of Biochemistry and Molecular Biology, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, 08028, Spain, 2Integrative
Neurobiology Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, National
Institutes of Health, Baltimore, Maryland 21224, 3Departrnent of Biochemistry and Molecular Biomedicine and Institute of Biomedicine, Faculty of Biology,
University of Barcelona, 08028 Barcelona, Spain, 4 Department of Biomedical Sciences, Marquette University, Milwaukee, Wisconsin 53233, 5 School of
Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, and 6Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section,
Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program, and National Institute on Alcohol
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Ghrelin receptor, also known as growth hormone secretagogue receptor (GHS-Rla), is coexpressed with its truncated isoform GHSRlb, which does not bind ghrelin or signal, but oligomerizes with GHS-Rla, exerting a complex modulatory role that depends on its
relative expression. D 1 dopamine receptor (DIR) and DSR constitute the two D1-like receptor subtypes. Previous studies showed that
GHS-Rlb also facilitates oligomerization of GHS-Rla with DIR, conferring GHS-Rla distinctive pharmacological properties. Those
include a switch in the preferred coupling of GHS-Rla from Gq to Gs and the ability of DlR/DSR agonists and antagonists to counteract GHS-Rla signaling. Activation of ghrelin receptors localized in the ventral tegmental area (VTA) seems to play a significant
role in the contribution of ghrelin to motivated behavior. In view of the evidence indicating that dopaminergic cells of the VTA
express ghrelin receptors and DSR, but not DIR, we investigated the possible existence of functional GHS-Rla:GHS-Rlb:DSR oligomeric complexes in the VTA. GHS-Rla:GHS-Rlb:DSR oligomers were first demonstrated in mammalian transfected cells, and their
pharmacological properties were found to be different from those of GHS-Rla:GHS-Rlb:DIR oligomers, including weak Gs coupling
and the ability of DlR/DSR antagonists, but not agonists, to counteract the effects of ghrelin. However, analyzing the effect of ghrelin
in the rodent VIA on MAPK activation with ex vivo experiments, on somatodendritic dopamine release with in vivo microdialysis
and on the activation of dopaminergic cells with patch-damp electrophysiology, provided evidence for a predominant role of GHSRla:GHS-Rlb:D lR oligomers in the rodent VTA as main mediators of the dopaminergic effects of ghrelin.
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Significance Statement
The activation of ghrelin receptors localized in the ventral tegmental area (VIA) plays a significant role in the contribution of ghrelin to motivated behavior. We present evidence that indicates these receptors form part of oligomeric complexes that include the
functional ghrelin receptor GHS-Rla, its truncated nonsignaling isoform GHS-Rlb, and the dopamine D1 receptor (DIR). The binding of ghrelin to these complexes promotes activation of the dopaminergic neurons of the VTA by activation of adenylyl cyclaseprotein kinase A signaling, which can be counteracted by both GHS-Rla and DIR antagonists. Our study provides evidence for a
predominant role of GHS-Rl a:GHS-Rl b:D IR oligomers in rodent VTA as main mediators of the dopaminergic effects of ghrelin.
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Introduction
The orexigenic hormone ghrelin acts as an internal signal for
animals to engage in food-directed behaviors (Silver and Balsam,
2010; Mason et al., 2014; Al Massadi et al., 2019). It is mainly
produced by the stomach oxyntic cells during anticipated mealtimes, and its blood levels decrease after meals (Silver and
Balsam, 2010). The hypothalamic arcuate nucleus is a major site
of expression for ghrelin receptors in the brain, specifically in the
cells that synthesize the neuropeptide agouti-related peptide.
Ghrelin reaches the arcuate nucleus by its proximity to the median eminence, where the blood-brain barrier is more permissive
and allows the passage of peptides (for review, see Ferre, 2017).
Agouti-related peptide neurons project to several hypothalamic
nuclei, as well as to the ventral tegmental area (VTA), and their
activation promotes feeding (Aponte et al., 2011 ; Krashes et al.,
2011 ; Betley et al., 2013). Ghrelin receptors are also expressed in
other brain regions, including the hippocampus, substantia
nigra, and VTA (Zigman et al., 2006). Several studies suggest
that the activation of the VTA dopaminergic system plays a significant role in the motivational function of ghrelin (Abizaid et
al., 2006; Jerlhag et al., 2007; Skibicka et al., 2011 ; Al Massadi et
al., 2019). The mechanisms proposed to be involved in such activation include direct peripheral transit of ghrelin to the VTA or
indirect activation through circuit-level effects of ghrelin from either peripheral or central origin (see Discussion).
The ghrelin receptor is a G-protein-coupled receptor (GPCR)
also known as growth hormone secretagogue receptor (GHSR),
or GHS-Rla. Cells expressing GHS-Rla also express GHS-Rlb, a
truncated isoform lacking transmembrane domains 6 and 7.
Although ghrelin is the canonical ligand for GHS-Rla, ghrelin
does not bind and does not signal through GHS-Rlb. However,
GHS-Rlb oligomerizes with GHS-Rla, exerting an expression
level-dependent modulatory role (Navarro et al., 2016). Low relative GHS-Rlb expression facilitates GHS-Rla function by promoting its trafficking to the plasma membrane, while a high
relative GHS-Rlb expression inhibits GHS-Rla function by
exerting a negative allosteric effect on GHS-Rla signaling (Mary
et al., 2013; Navarro et al., 2016).
Another functional role of GHS-Rlb is facilitating the oligomerization of GHS-Rla with other GPCRs, specifically with the
dopamine D 1 receptor (DlR), which was shown both in mammalian transfected cells and in striatal cells in culture (Navarro et
al., 2016). Among the pharmacological properties of the GHSRla:GHS-Rlb:DlR oligomer, ghrelin promoted adenylyl cyclase
(AC) activation, indicating a switch in the usually preferred Gq
coupling of GHS-Rla to the preferred Gs coupling of DlR
(Navarro et al., 2016). Other studies in mammalian transfected
cells and hippocampal neurons have also provided evidence for
the ability of GHS-Rla to heteromerize with DlR without
the involvement of GHS-Rlb, in which case ghrelin did not produce AC activation, while DlR could signal by coupling to Gq
(Jiang et al., 2006; Kern et al., 2015; Casanovas et al., 2021 ).
Immunohistochemical experiments in transgenic mice that
express GFP in cells also expressing GHS-Rla indicated a prominent colocalization of GHS-Rla and DlR in the hippocampus,
cortex, and mi db rain, in the substantia nigra and VTA (Jiang et
al., 2006; Kern et al., 2015). Therefore, we investigated whether
GHS-Rla:DlR complexes localized in the VTA constitute a significant population of GHS-Rla receptors mediating the dopaminergic effects of ghrelin.
Since some studies indicate that D5R is the predominant D 1like receptor localized in mesencephalic dopaminergic cells
(Ciliax et al., 2000; Khan et al., 2000), we aimed first at analyzing

the possible existence of oligomers of GHS-Rla, GHS-Rlb, and
D5R in mammalian transfected cells and comparing their pharmacological properties to those of GHS-Rla:GHS-Rlb:DlR
oligomers. We then evaluated the possible existence of these oligomeric complexes in the rodent VTA as well as their role in the
dopaminergic effects of ghrelin. Using different in vitro and in
vivo approaches, we obtained evidence for a predominant role of
GHS-Rla:GHS-Rlb:DlR oligomers, rather than Rla:GHS-Rlb:
D5R oligomers, in rodent VTA as the main mediators of the dopaminergic effects of ghrelin.

Materials and Methods
Vectors, fusion proteins, cell culture, and transfection. Human
cDNAs for GHS-Rla, GHSRlb, and D5R, cloned into pcDNA3.l, were
amplified without their stop codons using sense and antisense primers
harboring EcoRl and KpnI sites to clone D5R in the pRLuc-Nl vector
(pRLuc-Nl ; PerkinElmer Life Sciences) and GHS -Rl a or GHS-Rlb to
the pEYFP-Nl vector (enhanced yellow variant of GFP; Clontech) or
EcoRI and KpnI sites to clone GHS -Rl a in a GF?2-containing vector (pGFP2; Packard BioScience). Amplified fragments were subcloned to be
in frame with restriction sites of pRLuc-Nl , pEYFP-Nl, or p-GFP2 vectors to provide plasmids that express proteins fused to RLuc, yellow fluorescent protein (YFP), or GFP 2 on the C-terminal end (D5R-RLuc,
GHS-Rl a-YFP, GHS -Rlb-YFP, and GHS-Rla-GFP 2). HEK293T cells
were maintained at 37°C in an atmosphere of 5% CO2. They were grown
in DMEM (Thermo Fisher Scientific) supplemented with 2 mM L-glutamine, 100 µg/ml sodium pyruvate, 100 U/ml penicillin/streptomycin,
minimum Eagle's medium nonessential amino acid solution (1:100), and
5% (v/v) heat-inactivated FBS (all supplements were from Thermo
Fisher Scientific). HEK293T cells were transiently transfected with the
corresponding protein cDNA by the polyethylenirnine (PEI) (SigmaAldrich) method. Cells were incubated for 4 h with the corresponding
cDNA together with PEI (5.47 mM in nitrogen residues) and 150 mM
NaCl in a serum-starved medium. After 4 h, the medium was changed
to a fresh complete culture medium. Forty-eight hours after transfection,
cells were washed twice in quick succession in HBSS with 10 mMglucose,
detached, and resuspended in the same buffer, and used for bioluminescence resonance energy transfer (BRET), sequential resonance energy
transfer (SRET), and cAMP accumulation or ERKl/2 phosphorylation
experiments.
Resonance energy transfer-based assays. For BRET experiments,
HEK293T cells were transiently cotransfected with a constant cDNA
encoding for receptor-RLuc and with increasing amounts of cDNA corresponding to receptor-YFP (BRET 1) or receptor-GFP 2 (BRET 2). To
control the cell number, the sample protein concentration was determined using a Bradford assay kit (BIO-RAD) using bovine serum albu min dilutions as standards. To quantify fluorescence proteins, cells
(20 µg protein) were distributed in 96-well microplates (black plates with
a transparent bottom) and the fluorescence was read in a Fluostar
Optima fluorimeter (BMG Labtech) equipped with a high-energy xenon
flash lamp using a 10 nm bandwidth excitation filter at 410 nm for receptor-GFP2 reading or 485 nm for receptor-YFP reading. Receptor fluorescence expression was determined as fluorescence of the sample minus
the fluorescence of cells expressing receptor-Rluc alone. For BRET measurements, the equivalent of 20 µg of cell suspension was distributed in
96-well whlte microplates with whlte bottoms (Corning 3600, Corning)
and 5 µ,Mcoelenterazine H (for the YFP acceptor) or DeepBlueC (for the
GFP2 acceptor; Thermo Fisher Scientific) were added. Using DeepBlueC
or coelenterazine Has substrates results in respective 410- and 485 nm
emissions from RLuc, whlch allows the respective selective energy transfer to GFP 2 and YFP (Carriba et al., 2008). One minute after adding coelenterazine H or immediately after addition of DeepBlueC, BRET was
determined using a Mithras LB 940 reader (Berthold Technologies),
which allows the integration of the signals detected in the short-wavelength filter at 485 nm and the long-wavelength filter at 530 nm when
YFP is the acceptor or the short-wavelength filter at 410 nm and the
long-wavelength filter at 510 nm when GFP 2 is the acceptor. To quantify
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receptor-RLuc expression, luminescence readings were performed after
10 min of adding 5 µ,M coelenterazine H regardless of the acceptor used.
Net BRET is defined as [(long wavelength emission)/(short wavelength
emission)] - Cf, where Cf corresponds to [(long wavelength emission)/
(short wavelength emission)] for the RLuc construct expressed alone in
the same experiment. For SRET experiments (Carriba et al., 2008),
HEK293T cells were transiently cotransfected with constant amounts of
cDNAs encoding both the receptor fused to RLuc or GFP 2 and with
increasingly amounts of cDNA corresponding to the receptor fused to
YFP. Using aliquots of transfected cells (20 µg of protein), the following
different determinations were performed in parallel: quantification of
protein-YFP expression; and quantification of protein-RLuc expression
as described above. For SRET, cells were distributed in 96-well microplates, and 5 µ,M DeepBlueC was added. The SRET signal was collected
using a Mithras LB 940 reader with detection filters for short wavelength
(410nm) and long wavelength (530nm). By analogy with BRET, net
SRET is defined as [(long wavelength emission)/(short wavelength emission)] - Cf, where Cf corresponds to long wavelength emission/short
wavelength emission for cells expressing protein-RLuc and proteinGFP2. Linear unmixing was done for SRET quantification, taking into
account the spectral signature to separate the two fluorescence emission
spectra (Zimmermann et al., 2002). BRET and SRET are expressed as
milliBRET units (mBU) and milliSRET units (mSU); net BRET and net
SRETX 1000).
cAMP accumulation assay. Homogeneous time-resolved fluorescence energy transfer assays were performed using the Lance Ultra
cAMP kit (PerkinElmer Life Sciences). The optimal cell density was first
established for an appropriate fluorescent signal by measuring the timeresolved fluorescence resonance energy transfer (FRET) signal as a function of forskolin concentration using different cell densities. Forskolin
dose-response curves were related to the cAMP standard curve to establish which cell density provides a response that covers most of the
dynamic range of the cAMP standard curve. HEK293T cells growing in
medium containing SO µ,M zardaverine, a phosphodiesterase inhibitor,
were incubated for 15 min before either ghrelin or vehicle was added.
Fluorescence at 665 nm was analyzed on a PHERAstar Flagship microplate reader equipped with a homogeneous time-resolved fluorescence
energy transfer optical module (BMG Labtech).
Determination of phosphorylated ERKl /2 in HEK293T cells or in
VTA slices. Transfected HEK293T cells were cultured in serum-free medium for 16 h before the addition of any ligand. Cells or rat VTA slices
were treated or not with the indicated ligands for the indicated time (see
corresponding figures) and were lysed by the addition of 300 µ,l of icecold lysis buffer (SO mM Tris-HCl, pH 7.4, SO mM NaF, 150 mM NaCl, 45
mM /3-glycerophosphate, 1% Triton X-100, 20 µ,M phenyl-arsine oxide,
0.4 mM NaVO4 , and a protease inhibitor mixture). Cellular debris was
removed by centrifugation at 13,000 x g for 5 min at 4°C, and the protein was quantified by the bicinchoninic acid method using BSA dilutions as the standard. Phosphorylated proteins were then determined by
Western blot, using a mouse anti-phospho-ERKl/2 antibody (1:2500;
Sigma-Aldrich) and rabbit anti-total-ERKl/2 antibody (1:40,000; SigmaAldrich) to quantify phospho-ERKl/2. Bands were visualized by the
addition of a mixture of IRDye 800 (anti-mouse) antibody (1:10,000;
Sigma-Aldrich) and IRDye 680 (anti-rabbit) antibody (1:10,000; SigmaAldrich) and scanned by an Odyssey infrared scanner (LI-COR). Band
densities were quantified using the scanner software exported to Excel
(Microsoft). The level of phosphorylated proteins was normalized for
differences in loading using the total (phosphorylated plus nonphosphorylated) protein band intensities.
Animals. All animals used in the study were maintained in accordance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals, and the animal research conducted to perform this
study was reviewed and approved by the National Institute on Drug
Abuse (NIDA) Intramural Research Program (IRP) Animal Care and
Use Committee (protocol no. 18-MTMD-13), the Catalan Ethical
Committee for Animal Use (protocol CEANDMAH no. 4049 and no.
5664) and the Institutional Animal Care and Use Committee at
Marquette University (protocols AR-290 and AR-291). Male Sprague
Dawley rats (from the in-house colony of the Faculty of Biology,
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University of Barcelona or Charles River Laboratories) were used to
obtain VTA slices and for microdialysis experiments. Male GHS-R
CR1SPR/Cas9 knock-out (KO) Wistar rats and wild-type (WT) littermates (Zallar et al., 2019; in-house colony at NIDA IRP) were also used
in microdialysis experiments. Pitx3-eGFP( +) mice (Zhao et al., 2004),
provided by Kevin Wickman (University of Minnesota, Minneapolis,
MN) with permission from Meng Li (Cardiff University, Cardiff, UK),
and C57BL6/J mice from the in-house colony at Marquette University
(Milwaukee, WI) were used for electrophysiology experiments.
Rat VTA slice preparation. Male Sprague Dawley rats (2months old)
were killed by decapitation under 4% isoflurane anesthesia, and brains
were rapidly removed, placed in ice-cold oxygenated (O 2/CO 2, 95%/5%)
Krebs-HCO 3 - buffer (in IDM: 124 NaCl, 4 KC!, 1.25 KH 2PO4 , 1.5 MgCl2,
1.5 CaC12, 10 glucose, and 26 NaHCO 3, pH 7.4), and sliced at 4°C using
a brain matrix (Zivic Instruments). VTA slices (500 µm thick) were dissected at 4°C in Krebs-HCO 3 - buffer; each slice was transferred into a
12-well plate with Corning Netwell inserts containing 2 ml of ice-cold
Krebs-HCO 3 - buffer. The temperature was raised to 23°C, and, after
30 min, the medium was replaced by 2 ml of fresh buffer (23°C). Slices
were incubated under constant oxygenation (O 2/CO 2, 95%/5%) at 30°C
for 4 h in an Eppendorf Thermomixer (S'), and the medium was
replaced by fresh buffer and incubated for 30 min before the addition of
any ligand. After incubation, the solution was discarded, and slices were
frozen on dry ice and stored at 80°C until ERKl/2 phosphorylation was
determined.
In vivo microdialysis. Male Sprague Dawley rats, GHS-R CRISPR/
Cas9 KO Wistar rats, or their WT littermates (3 months old) were used.
Experiments were performed during the light cycle. Rats were deeply
anesthetized with 3 ml/kg Equithesin (4.44 g of chloral hydrate, 0.972 g
of Na pentobarbital, 2.124 g of MgSO4 , 44.4 ml of propylene glycol, 12
ml of ethanol, and distilled H 2O up to 100 ml of the final solution;
NIDA Pharmacy) and implanted unilaterally in the VTA (coordinates in
millimeters from bregma with a 10° angle in the coronal plane: anterior,
-5.6; lateral, 2.4; vertical, -9) with a specially designed microdialysis
probe that allows the direct infusion of large peptides within the sampling area (Navarro et al., 2015). Some animals were implanted simultaneously with two regular probes, one in the VTA and the second one in
the ipsilateral shell of the nucleus accumbens (NAc; coordinates in millimeters from bregma: anterior, 1.6; lateral, 0.5; vertical, -5.1) with a regular microdialysis probe. After surgery, rats were allowed to recover in
hemispherical cages (model CMA 120, CMA Microdialysis) equipped
with two-channel overhead fluid swivels (Instech) connected to a sample
collector (model CMA 470, CMA Microdialysis). Twenty-four hours after implanting the probes, experiments were performed on freely moving rats in the same hemispherical home cages in which they recovered
overnight from surgery. An artificial CSF (ACSF) containing (in mM)
144 NaCl, 4.8 KC!, 1.7 CaCl 2, and 1.2 MgC1 2 was pumped through the
probe at a constant rate of 1 µI/min. After a washout period of 90 min,
dialysate samples were collected at 20 min intervals. For peptide infusion, ghrelin and the liver expressed antimicrobial peptide 2 (LEAP2), an
endogenous antagonist of GHS-Rl a (Ge et al., 2018), and were dissolved
in ACSF to a final concentration of 10 µ,M. The peptides were injected
with a 1 µ1 syringe (Hamilton) driven by an infusion pump and coupled
with silica tubing (inner diameter, 73 µm; Polyrnicro) to the microdialysis probe infusion cannula (dead volume, 40 nl), which was primed with
ACSF and plugged during implantation and delivered at a rate of 16.6
nl/min. The GHS-Rl a antagonist YL781, the DlR/DSR antagonist
SCH23390, and the protein kinase A (PKA) inhibitor H-89 were administered within the VT A by constant perfusion by reverse dialysis within
the VTA (all at 10 µ,M). At the end of the experiment, rats were given an
overdose ofEquithesin, the brains were extracted and fixed in formaldehyde, and probe placement was verified using cresyl violet staining.
Dopamine content was measured by HPLC coupled with a coulometric
detector (5200a Coulochem III, ESA).
Patch-clamp electrophysiology. Horizontal slices containing the VTA
(225 µ,m) were prepared as described in detail previously (Kotecki et al.,
2015) from 6- to 8-week-old Pitx3-eGFP( +) or C57BL6/J mice using
previously identified putative dopaminergic neuron characteristics
(Cruz et al., 2004; Arora et al., 2011 ). Results did not differ from those in
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EGFP+ cells and thus were combined. Current-damp recordings were
performed at 32-34°C using borosilicate electrodes (2.5-4.S MD) filled
with a K-gluconate solution (Hearing et al., 2013; Anderson et al., 2019)
to assess spontaneous activity (I= O). Upon achieving whole cell, cells
were permitted to stabilize over a 2-5 min period before drug application. Drugs were bath applied using a gravity perfusion system at a rate
of2-2.S ml/min. Each drug was applied for at least 5 min, with measures
of frequency taken only after at least three consecutive sweeps of stable
firing was obtained. For studies involving receptor antagonists (eticlopride, SCH39166, JMV2959), drugs were applied before and during subsequent application of ghrelin. Drug concentrations were as follows:
ghrelin, 500 nM; SCH39166, 10 µ,M; JMV2959, 10 µ,M; and eticlopride, 2
Jl,M.

Statistics. Parametric statistics (paired or nonpaired t test, one-way,
bifactorial, or repeated-measures ANOVA followed by Dunnett's or
Tukey's multiple-comparison test) were used, since the different groups
analyzed showed normality and homogeneity of variance. For patchclamp electrophysiological experiments, paired t test or repeated-measures ANOVA were used because measures (neural spike firing) were
taken two or three times (baseline vs postdrug vs postdrug combinations) within the same cell to determine whether the mean difference
between the repeated observations is zero. Details of the statistical analysis for each experiment, statistical test, sample size, and degree of significance are described in the corresponding figure legend. GraphPad Prism
software version 7 was used for the statistical analysis.

Results
GHS-Rlh-dependent oligomerization ofGHS-Rla with DSR
The biophysical techniques Bioluminescence Resonance Energy
Transfer BRET' and BRET2 and SRET were performed in HEK293T
cells transfected with different combinations of D5R fused to RLuc
(D5R-RLuc), GHS-Rla fused to YFP (GHS-Rla-YFP), or GFP2
(GHS-Rla-GFP2) and either nonfused GHS-Rlb or GHS-Rlb fused
to YFP (GHS-Rlb-YFP). In BRET' and BRET2, RLuc was used as
the donor chromophore, but with two different RLuc substrates, coelenterazine H and DeepBlueC, which induce two different bioluminescent light emissions (485 and 410 nm, respectively), allowing
energy transfer to a close YFP or GFP2 acceptor chromophore,
respectively. These acceptors emit 530 nm (YFP) or 510 nm (GFP2)
light, which can either be detected (for the respective BRET' or
BRET2 measurements) or result in a FRET to a second acceptor
chromophore (for SRET measurements). In SRET, YFP was used as
the second acceptor on transfer of energy from GFP2, which was the
first acceptor from DeepBlueC-induced Rluc bioluminescence (for
detailed description of techniques, see Carriba et al., 2008).
Saturation BRET', BRET2 , and SRET experiments were performed to support a specific interaction between the receptors
fused to the corresponding chromophores from a nonspecific
random collision. Energy transfer was then determined using the
same transfected quantities of the receptor fused to the donor
(and the first acceptor in SRET experiments) versus increasing
quantities of the receptor fused to the acceptor chromophore (or
second acceptor in SRET experiments; Carriba et al., 2008).
Under the present experimental conditions, a BRET saturation
curve, indicative of oligomerization, could be obtained with
BRET' experiments in cells transfected with D5R-RLuc and
GHS-Rlb-YFP (Fig. l C), but not with GHS-Rla-YFP, which
showed a straight line, indicative of nonspecific random collision
(Fig. l A) . The same lack of saturation was also observed with
BRET2 experiments in cells transfected with D5R-RLuc and
GHS-Rla-GFP2 (Fig. l B). Nevertheless, a clear saturation curve
was obtained when the cells were cotransfected with nonfused
GHS-Rl b (Fig. l B). In the same way, a clear saturation curve was
obtained in SRET experiments in cells transfected with D5R-
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RLuc, GHS-Rla-GFP 2, and GHS-Rlb-YFP (Fig. lD). These
results indicate that, the same as with DlR (Navarro et al., 2016),
GHS-Rlb facilitates oligomerization of D5R with GHS-Rla.
Since GHS-Rlb, but not GHS-Rla, oligomerizes with D5R, these
results strongly suggest that GHS-Rlb establishes the link
between D5R and GHS-Rla in the GHS-Rla:GHS-Rlb:D5R
oligomer.

Differences between the signaling of GHS-Rla:GHS-Rlb:
DIR and GHS-Rla:GHS-Rlb:DSR oligomers in mammalian
transfected cells
The inability of GHS-Rlb to bind ghrelin and signal indicates
that any differential interaction between GHS-Rla and DlR/
D5R ligands that depends on the presence of GHS-Rlb is dependent on the formation of GHS-Rla:GHS-Rlb:DlR or GHSRla:GHS-Rlb:D5R oligomers. In our previous study, both DlR/
D5R agonists and ghrelin were able to produce a Gs-dependent
cAMP formation upon GHS-Rla:GHS-Rlb:DlR oligomerization
(Navarro et al., 2016). The analysis of cAMP formation showed
that coadministration of ghrelin and the DlR/D5R agonist
SKF81297 did not produce an additive effect, indicative of negative cross talk (Navarro et al., 2016). Also dependent on GHSRla:GHS-Rlb:DlR oligomerization, the DlR/D5R antagonist
SCH23390 counteracted the effects of both SKF81297 and ghrelin on cAMP formation. In addition, the GHS-Rla antagonist
YIL781 also counteracted the effects of both ghrelin and
SKF81297. In the present study, we also analyzed the effect of
ghrelin on cAMP formation in HEK293T cells cotransfected
with GHS-Rla and DlR cDNA and increasing amounts of
GHS-Rlb cDNA (Fig. 2A), with parallel experiments in cells
cotransfected with GHS-Rla, D5R, and increasing amounts of
GHS-Rlb (Fig. 2B). The results from cells transfected with the
DlR reproduced our previous finding of a ghrelin-induced
cAMP accumulation facilitated by cotransfection with GHSRl b (Navarro et al., 2016). Also, as previously shown, the effect
of ghrelin (100 nM) depended on the GHS-Rlb/GHS-Rla
cDNA ratio, following an inverted u-shaped curve, with an
increase of 26%, 72%, 46% and 15% versus control values at
cDNA ratios of O, 0.3, 1, and 2, respectively (Fig. 2A). Different
from our previous studies (Navarro et al., 2016; Casanovas et
al., 2021 ), the small effect of ghrelin observed in the absence of
GHS-Rlb reached statistical significance (Fig. 2A). This would
agree with GHS-Rla being still able to induce a certain degree
of activation of Gs when cotransfected with DlR and in the absence of GHS-Rlb. On the other hand, ghrelin (100 nM) was
practically ineffective at promoting cAMP accumulation when
cotransfected with GHS-Rlb and D5R and only showed a small
but significant effect (26% increase vs control) at a GHS-Rlb/
GHS-Rla ratio of 0.3 (Fig. 2B).
If comparable, the results with cAMP accumulation would
indicate a clear difference in the functional properties of the D,like receptors on oligomerization with GHS-Rla and GHS-Rlb,
with DlR, but not D5R, increasing the ability of ghrelin to signal
through Gs and activate AC. Therefore, the same cells (HEK293T)
and transfection methodology (amount ofDlR or D5R cDNAs as
well as GHS-Rla and GHS-Rlb cDNAs, at a GHS-Rlb/GHS-Rla
ratio of O or 0.3) was applied to compare differences between
GHS-Rla:GHS-Rlb:DlR and GHS-Rla:GHS-Rlb:D5R oligomers
on MAPK signaling, which does not necessarily depend on Gs
activation. We first analyzed the effect of different concentrations
and incubation times of ghrelin and SKF81297 in HEK293T cells
transfected with either D5R (Fig. 3A) GHS-Rla (Fig. 3B), or GHSRlb (Fig. 3C) on ERKl/2 phosphorylation. Fused receptors were

944 • J. Neurosci., February 9, 2022 • 42(6):940-953

Navarro et al. • Ghrelin-Dopamine Receptor Oligomers in the VT A

A

B
50

80

''

40
::J

co

30

E 20
10

60
:::,

~

40
20

o.-=-~---~--.--~~
0
10
20
30
40
50
60
70

50

YFP/RLu c

C

100
GFP2/Rluc

200

150

D
200

60

!!

150

c

::J 40

co

~

tii

E

100

II::
(I)

20

50

0+-0

~ -

-.--

-.--

-.--

-.--

-,

20

40

60

80

100

120

0
0

100

200

GHS-R1a

GHS-R1b

300

400

500

YFP/Rluc

YFP/Rluc

Rluc

0

YFP

0

GFP'I
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used to demonstrate their functionality. As expected, ghrelin was
effective in cells transfected with GHS-Rla (Fig. 3B), but not with
GHS-Rlb (Fig. 3C). From the results of the different agonist concentrations and time exposures (Fig. 3), 100 nM SKF81297 and 50
nM ghrelin and a time of incubation of 7 min were selected as
most appropriate to analyze the effect of different ligand interactions on MAPK signaling in cells cotransfected with GHS-Rla
with or without GHS-Rlb and DSR (Fig. 4) or DlR (Fig. 5). In
both cases, SKF81297 and ghrelin were effective and produced the
same effect in the absence (Figs. 4A, SA) or presence ofGHS-Rlb
(Figs. 4B, SB). Remarkably, ghrelin was very effective in cells transfected with DSR, indicating that the scarce activating effect of AC
in cells cotransfected with GHS-Rla, GHS-Rlb, and DSR versus
those cotransfected with GHS-Rla, GHS-Rlb, and DlR was not
dependent on a general reduction of DSR function, but on the
selective ability of the DlR to promote a ghrelin-mediated Gs activation in the GHS-Rla:GHS-Rlb:DlR oligomer.
The comparison of the compound effect of ghrelin and
SKF81297 uncovered another pharmacodynamic difference that
depends on the D 1-like receptor subtype. Only in cells cotransfected with GHS-Rla, GHS-Rlb, and DlR was there evidence for
negative cross talk on coadministration of ghrelin and SKF81297
(Fig. SB) . On the other hand, negative cross talk was not
observed in cells cotransfected with GHS-Rla, GHS-Rlb, and

DSR, where coadministration of both agonists produced an additive response (with the effect of the compound administration
being significantly higher than that of SKF81297 alone; Fig. 4B).
These results would also complement the previously reported
selective negative cross talk on AC signaling in cells cotransfected
with GHS-Rla, GHS-Rlb, and DlR, but not in cells not cotransfected with GHS-Rlb, indicating its dependence on GHS-Rla:
GHS-Rlb:DlR oligomerization (Navarro et al., 2016).
As an orthogonal measure from the negative cross talk
between agonists, a strong cross-antagonism of the DlR/DSR antagonist SCH23390 and the GHS-Rla antagonist YL781 (Esler et
al., 2007) could be demonstrated in cells cotransfected with either DSR or DlR and GHS-Rla, but only when also cotransfected with GHS-Rlb (compare Figs. 4D, SD, and 4C, SC). Thus,
in cells expressing DSR and GHS-Rla, but in the absence of
GHS-Rlb, the ability of ghrelin to activate GHS-Rla and produce ERKl/2 phosphorylation could only be counteracted by the
GHS-Rla antagonist YL781 (1 µM; Fig. 4C), while it could also
be counteracted by the DlR/DSR antagonist SCH23390 (1 µM)
in the presence of GHS-Rlb (Fig. 4D). Likewise, the ability of the
DlR/DSR agonist SKF81297 to activate MAPK signaling could
only be counteracted by SCH23390 in the absence of GHS-Rlb
(Fig. 4C) and was also counteracted by YIL781 in the presence of
GHS-Rlb (Fig. 4D). This same pattern was observed when DlR
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Figure 2. Analysis of cAMP accumulation in HEK293T cells expressing GHS-Rla, GHS-Rlb,
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(1 µg) and D1R cDNA (1 µg) in the presence of increasing amounts of GHS-Rlb cDNA (O,
0.3, 1, or 2 µg). 8, Cells were transfected with GHS-Rla cDNA (1 µg) and DSR cDNA (1 µg)
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were analyzed after the addition of ghrelin (SO nM) or vehicle and are expressed as the percentage of cells treated with vehicle and not transfected with GHS-Rl b (broken line), and
are represented as the mean ±: SEM of six experiments perfonned in triplicate. In A, a bifactorial ANOVA demonstrates a significant effect of ghrelin (,p < 0.0001) and GHS-Rlb
(,p < 0.0001); significantly different versus the respective vehicle-treated control group:
*p < 0.05, ***p < 0.001, and ***p < 0.0001, respectively; Tukey's multiple-comparison
test. In 8, a bifactorial ANOVA demonstrates a significant effect of ghrelin (,p < 0.05) without
a GHS-Rlb effect; significantly different versus the respective vehicle-treated control group:
*p < 0.05; Tukey's multiple-comparison test.

was present in the oligomeric complex, instead of DSR (Fig. SC,
D). Thus, the presence of GHS-Rlb induces the ability of GHSRla and DlR/DSR antagonists to respectively cross-antagonize
DlR/DSR and GHS-Rla agonists, which is consistent with its
proposed role in supporting oligomerization between GHS-Rla
and DlR or DSR.
MAPK signaling of GHS-Rla:GHS-Rlb:DIR oligomers in
theVTA
Ghrelin and SKF81297-induced ERKl/2 phosphorylation were
then evaluated in VTA slices of Sprague Dawley rats using a previously reported method that allowed the study of MAPK signaling of other GPCR complexes (Navarro et al., 2015; Moreno et
al., 2017; see also Materials and Methods). As in previous studies,
higher ligand concentrations were used compared with

transfected cell preparations to allow sufficient penetration into
the tissue. At 500 TIM, both ghrelin and the DlR agonist
SKF81297 produced a significant increase in ERKl/2 phosphorylation, but not when coadministered, which is indicative of a
negative cross talk (Fig. 6). The effects of both agonists were
counteracted by either antagonist, SCH23390 or YL781 (at 5
µ,M), which is indicative of cross-antagonism (Fig. 6). That this
cross-antagonism represents a biochemical characteristic of
GHS-Rla:GHS-Rlb:DlR and GHS-Rla:GHS-Rlb:DSR oligomers implies that either of them could represent a major population of functional GHS-Rla receptors in the VTA. In addition, to
our knowledge, there are not available ligands that can discriminate between DlR and DSR, including SKF81297 and
SCH23390. While not conclusive, the evidence of negative cross
talk between ghrelin and SKF81297, which was specific for DlR
in HEK293T cells, is more consistent with DlR as the predominant D 1-like receptor forming functional complexes with GHSRla and GHS-Rlb in the VTA.
GHS-Rla:GHS-Rlb:DIR oligomer-mediated modulation of
dopaminergic neuronal function in the VT A
The local application of ghrelin in the rodent VTA has been previously shown to promote an increase in the activity of the dopaminergic neurons with an increase in their firing rate (Abizaid et
al., 2006) and in dopamine release in the ipsilateral NAc CTerlhag
et al., 2007) using patch-clamp electrophysiology in brain slices
and in vivo microdialysis, respectively. The lack of availability of
specific antagonists hampered the demonstration of the specific
involvement of GHS-Rla in these effects of ghrelin. Nevertheless,
brain slices from GHSR KO mice were used in the electrophysiological experiments and were shown to be insensitive to the effect
of ghrelin (Abizaid et al., 2006). Selective and potent small-molecule GHS-Rla competitive antagonists have now been developed,
such as YIL781 (Esler et al., 2007) and JMV2959 (Moulin et al.,
2007, 2013). In addition, an endogenous antagonist of GHS-Rla,
LEAP2, has recently been discovered (Ge et al., 2018). LEAP2 is
mainly produced in the liver and small intestine. Its secretion is
suppressed by fasting and has been shown to block the effects of
ghrelin in vivo, including food intake, growth hormone release,
and maintenance of viable glucose levels during chronic caloric
restriction (Ge et al., 2018). Although it was initially characterized
as a negative allosteric modulator (Ge et al., 2018), subsequent
studies indicate that it is an inverse agonist (M'Kadmi et al., 2019).
By using a previously described in vivo microdialysis technique that allows the slow infusion of large peptides (Navarro
et al., 2015; Moreno et al., 2017; Cai et al., 2019), we fust investigated the ability of the local application of ghrelin and LEAP2,
alone and in combination, to modulate the respective somatodendritic and terminal release of dopamine in the VT A and ipsilateral NAc. The recently developed and characterized GHSRla CRISPR/Cas9 KO Wistar rat and WT littermates (Zallar et
al., 2019 ) were used to further demonstrate the dependence on
GHS-Rla of the pharmacological effects of ghrelin and LEAP2.
As previously reported by Jerlhag et al. (2007) with a bolus infusion (1 µg in 1 µl in 1 min), the slow local infusion of ghrelin
(10 µ,M at 16 nl/ml) in the VTA of WT rats produced a significant increase in the extracellular levels of dopamine in the ipsilateral NAc (Fig. 7A). Furthermore, we demonstrate that ghrelin
induces a significant somatodendritic dopamine release (Fig. 7A).
This is expected since local dopamine release in the VTA is a correlate of dopaminergic cell firing, which is induced by the antidromic
propagation of action potentials (Legault and Wise, 1999). On the
other hand, somatodendritic dopamine release promotes activation
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of inhibitory autoreceptors of the dopamine D 2
receptor subtype (D2-autoreceptors), with the
consequent inhibition of cell excitability, limiting excessive neuronal activation (Adell and
Artigas, 2004). As expected, ghrelin was ineffective in GHS-R KO rats, and no significant
changes were observed with the extracellular
levels of dopamine in the VTA or in the ipsilateral NAc (Fig. 7B). Less expected was the lack
of effect of the VTA infusion of LEAP2 (10 µ,M)
in the VTA or ipsilateral NAc of WT rats (Fig.
7C), since there is in vitro and in vivo evidence
for a significant constitutive activity of GHSRla (Petersen et al., 2009; Damian et al., 2012;
M'Kadmi et al., 2019). Nevertheless, coinfusion
of LEAP2 completely counteracted the effect of
ghrelin (both at 10 µ,M; Fig. 7D).
The effect of the slow local infusion of
ghrelin on the somatodendritic dopamine
release in the VTA was then evaluated in
Sprague Dawley rats to compare with the efficacy of other previously reported neuropeptides
using the same rat strain and methodology. At
the same concentration (10 µ,M), ghrelin produced a much larger dopamine release
(> 200%; Fig. 6E) compared with orexin-A or
endomorphin-1 (< 100% in both cases;
Navarro et al., 2015; Moreno et al., 2017).
Constant perfusion by reverse dialysis within
the VTA of the GHS-Rla antagonist YL781 (10
µ,M) or the DlR/DSR antagonist SCH23390 (10
µ,M) counteracted the dopamine-releasing effect
of ghrelin (Fig. 7E). Finally, the perfusion of the
PKA inhibitor H-89 (10 µ,M) also completely
counteracted the effect of ghrelin (Fig. 7E). The
cross-antagonism by SCH23390 supports that
GHS-Rla:GHS-Rlb:D 1-like receptor oligomers
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for 7min with ghrelin (SO nM), the D1 R/DSR agonist SKF81297 (100 nM) or both compounds. In Cand 0, cells were also
treated for 7 min with either ghrelin (SO nM) or SKF81297 (100 nM), after previous treatment for 10min with the GHSRla antagonist YL781 (1 µ.M) or the D1R/DSR antagonist SCH23390 (1 µ.M) . Phosphorylated ERKl/2 levels are expressed
as a percentage of nontreated cells (broken line) and are represented as the mean ± SEM of six to eight different
experiments performed in duplicate; significantly different versus cells only treated with SKF81297: #p < 0.05 and
##p < 0.01, respectively; one-way ANOVA followed by Tukey's multiple-comparison test; significantly different versus
nontreated cells: **p < 0.01 and ***p < 0.001, respectively; one-way ANOVA followed by Tukey's multiple-comparison
test.

J. Neurosci., February 9, 2022 • 42(6):940-953 • 947

Navarro et al. • Ghrelin-Dopamine Receptor Oligomers in the VTA

localiz.ed in the VTA play a significant role
in the modulation of the dopaminergic cell
function.
The inhibitory effect of the PKA
C
~
250
300
0
#
.,
inhibitor indicates a significant role of Gs:;
***
**
~=
200
AC-cAMP signaling in the dopamine~=
0 .,
0.,
.c "'
releasing effect of ghrelin, which is again
.c
"'
Q..,
~ ~ 150
"'.&J
consistent with the interpretation that
0 ....
io
.c 0
Q.~ 100 ..
GHS-Rla:GHS-Rlb:DlR, rather than
Q.~
~~
~e....
GHS-Rla:GHS-Rlb:DSR, oligomers repre....l.::
50
~
sent
the functionally dominant population
0::
0::
w
w
0
of GHS-Rla receptors in the VTA.
However, the counteracting effect of
the SCH23390 on ghrelin-induced somatodendritic dopamine release could just
be an apparent cross-antagonism, since it
D 01R + GSH-R1a + GSH-R1b
C
has been previously shown that D 1-like
01R + GSH-R1a
C
250
receptors localized in the VTA dopamiC
250
.2
.S!
nergic cells facilitate the desensitization
**
_N
200
_N 200 ***
t':'=
of
D2-autoreceptors on prolonged expoc.':'=
0 .,
0.,
sure
to dopamine or D2R agonists
'a=
150
150
"'.&J
"'.&J
0 ....
(Nimitvilai
and Brodie, 2010; Nimitvilai
0 ....
.c 0
.t::. o 100
a.~ 100
et al., 2012a, b), and the application of
Q. ~
~ ~
....l.::~e.... 50
DlR/DSR antagonists can prevent this
50
~
0::
desensitization
(Nimitvilai and Brodie,
0::
w
w
2010 ). Another possible mechanism re0
sponsible for the counteracting effect of
the SCH23390 could be its also demonstrated agonism on serotonin 5-HT2c
receptors {5-HT2CRs; Millan et al., 2001),
which are localized in GABAergic and doFigure S. Comparison of ligand-induced ERKl /2 phosphorylation in HEK293T cells expressing D1 Rand GHS-Rla with or without
paminergic cells in the VT A (Bubar and
GHS-Rlb. A, C, Cells were transfected with D1R and GHS-Rla cONA (1 µgin both cases). 8, D, Cells were transfected with D1R cDNA
Cunningham, 2007), where they appear
(1 µg), GHS-Rla cDNA (1 µg), and GHS-Rlb cONA (OJ µg). In A and 8, cells were treated for 7 min with ghrelin (SO nM), the D1R/
to mediate an inhibitory influence of seroDSR agonist SKF81297 (100 nM), or both compounds. In ( and D, cells were also treated for 7 min with either ghrelin (SO nM) or
SKF81297 (100 nM) after previous treatment for 10 min with the GHS-Rla antagonist YL781 (1 µ.M) or the D1R/DSR antagonist
tonin on dopamine neurotransmission
SCH23390 (1 µ.M). Phosphorylated ERKl/2 levels are expressed as a percentage of nontreated cells (broken line) and are represented
(Bubar
and
Cunningham,
2006).
as the mean ::':: SEM of six to eight different experiments performed in duplicate); significantly different versus cells only treated with
Therefore, we also performed electrophySKF81297: #p < 0.05; one-way ANOVA followed by Tukey's multiple-comparison test; *,** and ***: significantly different versus nonsiologic measurements in identified VT A
treated cells: *p < 0.05, **p < 0.01, and ***p < 0.001, respectively; one-way ANOVA followed by Tukey's multiple-comparison test.
dopaminergic neurons, controlling the inhibitory role of D2-autoreceptors {with
the addition of the D2R antagonist etiVTAslices
clopride) and using the selective DlR antagonist SCH39166,
200
which does not bind to 5-HT2CR (Wamsley et al., 1991).
**
C
*
We initially examined whether ghrelin influences the firing
.S!
cu 150
properties of VT A dopaminergic neurons with whole-cell patch~=
0 .,
clamp recordings in C57BL6/J (WT) mice using classical electro.c
"'
Q. .,
physiological properties to identify putative dopaminergic neu"'.&J 100
0 ....
.c 0
rons. Because of the unexpected variability of the effect of ghrelin
Q.~
(increased or decreased firing), subsequent studies were performed
~e....
....l.:: 50
in mice with C57BL6/J background expressing eGFP under the
0::
w
control of the promoter for the dopaminergic neuron-specific transcription factor Pitx3 (Pitx3-eGFP; Zhao et al., 2004; Fig. 8A). This
0
genetic approach represents a more reliable method than classical
electrophysiological measures for the identification of dopaminergic
neurons, and there are numerous publications that have validated
the use of Pitx3 mice to identify dopaminergic neurons (Labouebe
Figure 6. Analysis of ligand-induced ERKl/2 phosphorylation in rat VTA slices. ERKl/2
et al., 2007; Kotecki et al., 2015; McCall et al., 2017). In fact, VTA
phosphorylation was determined in rat VTA slices pretreated for 3 h with medium. Slices
dopaminergic neurons are now known to be composed of a phenowere then incubated for 20 min with medium, the GHS-Rla antagonist YIL781 (5 µ.M), or
typical heterogenous population of neurons that differ in their prethe D1R/DSR antagonist SCH23390 (5 µ.M), and were treated for 12 min wtth medium, ghreviously
thought unique electrophysiological profile, which included
lin (500 nM), the D1R/DSR agonist SKF81297 (500 nM), or both. Phosphorylated ERKl /2 levels
the presence of a large hyperpolarization-activated cation current
are expressed as a percentage of nontreated slices (broken line) and are represented as the
(Jh), long action potential durations, narrow range of basal firing
mean ::':: SEM of four to five slices; significantly different versus nontreated slices: *p < 0.05
frequency, and a capacity for inhibition by D2R agonists, related to
and **p < O.Dl, respectively; one-way ANOVA followed by Tukey's multiple-comparison
test.
D2 autoreceptor-mediated feedback inhibition via somatodendritic

A

'[ =

01R + GSH-R1a

B

01R + GSH-R1a + GSH-R1b

948 • J. Neurosci., February 9, 2022 • 42(6):940-953

Navarroet al. • Ghrelin-Dopamine Receptor Oligomersin theVT A

dopamine release (Ford et al., 2006;
A
B
WT
GHSR-KO
400
400
Lammel et al., 2008; Margolis et al., 2008;
--o- VTA
--o- VTA
--0- NAc
Morales and Margolis, 2017). Only one of
fil
j 300
those measures, Jh, was used to identify dopaminergic neurons in the study by
) 200
Abizaid et al. (2006), which showed a signi0
0
ficative ghrelin-induced increase in action
c ,oo --~
c,oo-,.-,
kz...o-<r- - - - - - - <{
a
c3
potential frequency in putative dopaminerO~,.......,"""T_G._,hr,...eli..,.
·n"'-T---,-~,.......,"""T--r-i
O~.---.---.---+-G--,
hr,...
el'in"'T--r-..-.---r---r---r--i
igic cells from rat and mouse VTA.
/§' ,.<:> !f> C> ,& ~ ,J> ,§> ...<S> -..<6> ...~ ...,.;, ._<§'#'
'if'-~ !f> C> ,& ~ ,J> <8',<S>-..<6>,~ ...rJ>$'ef'
Spontaneous action potentials were
time(min)
lime(min)
recorded in current clamp (I= O). For the
initial assessment of the effect of ghrelin,
WT
WT
D
C
--o-- VTA
400
400
--o- VTA
the baseline firing frequency in cells col--o-- NAc
lected from C57BL6/J mice (WT; n = 6)
and Pitx:3 mice (n = 5; Fig. SB) did not
differ significantly (WT, 3.47 ::!: 1.3 Hz;
Pitx:3, 5.40 ::!: 2.1 Hz; nonpaired t test,
0
c,oo
p =0.412). These data were therefore
c3
combined to illustrate the variable effect
O~,.......,"""T-LEA
;;;,a..aP"r2""-r-...,....~,.......,"""T--r-i
of ghrelin. Following at least 3-5 min of
:,.~_...,&:,.<S' 'If' 'if' f> !f> C> ,& ~ ,J> ,§>-..<S>-..<6' ...~
'if'-~ !f> C> ,& ~ ,J> <8',<S>-..<6' ...~ ...rJ'$'ef'
stable recording of action potentials, 0.5
time(min)
lime(min)
µ,M ghrelin was applied via bath perfusion. Within-cell comparisons initially
--o- Ghrelin
E
--o- YIL781 + Ghrelin
showed that while 10 of 11 cells exhibited
-o- SCH23390 + Ghrelin
a significant change in firing frequency
--o- H--89 + Ghrelin
IIIIID YIL, SCH or H-89 perfusion
(> 20% change), there was no significant
400
effect of ghrelin on action potential frequency (Fig. SB; paired t test, p = 0.49).
Subsequent examination of within-cell
effects of ghrelin compared with baseline
revealed that five cells exhibited an
increase in firing frequency, while five
showed a reduction in firing rate. Post
:,.~_...,&:,.<S' 'If' /§' f> !f> C> ,& ~ ,J> ,§>-..<S>-..<6'._.;,
hoc analysis of these two populations
time(min)
showed a mean 65% increase in firing
frequency compared with baseline (baseFigure 7. Activation of VTA dopaminergic cells by ghrelin: microdialysis experiments. A-0, Somatodendritic and NAc dopaline, 2.45 ::!: 0.55 Hz; ghrelin, 4.28 ::!: 1.2
mine release in GHS-Rl CRISPR/Cas9 KO Wistar rats (GHSR-KO) and WT; values represent dopamine concentrations from the
Hz; paired t test, p =0.052), whereas five
VTA and the ipsilateral NAc, represented as the mean ::'::: SEM (n =7- 14/group) of the percentage of baseline (average of three
showed a mean 47% reduction in firing
samples before infusion of ghrelin or LEAP2); white or gray rectangles on the x-axis: periods of infusion of ghrelin or LEAP2 (10
(baseline, 6.75 ::!: 2.13; ghrelin, 3.64 ::!:
µ.M for both peptides). E, Somatodendritic dopamine release in Sprague Dawley rats; values represent dopamine concentrations
1.60; paired t test, p =0.034). This differfrom the VTA, represented as the mean ::'::: SEM (n =7- 14/group) of the percentage of baseline (average of three samples
before infusion of ghrelin); white or lined rectangles on the x-axis: periods of infusion of ghrelin or perfusion (reverse dialysis)
ential effect of ghrelin could depend on
of the GHS-Rl a antagonist YIL781, the D1 R/DSR antagonist SCH23390, or the PKA inhibitor H-89 (10 µ.M for all compounds).
the already established existence of two
Filled symbols represent significantly different means compared with the mean of the first three basal values (p < 0.05,
subsets of VTA dopaminergic neurons,
repeated-measures
ANOVA followed by Dunnett's multiple-comparison test).
with different sensitivity to D2-autoreceptor-mediated inhibition. The subset
elevated firing rates compared with ACSF baseline (Fig. SC).
less sensitive to D2-autoreceptor inhiHowever, coapplication of eticlopride and ghrelin led to a
bition is species dependent and seems to be mostly represignificant increase in firing in five of five cells (repeatedsented by dopaminergic cells projecting to the amygdala and
measures ANO VA, p < 0.001; Fig. SC) with a mean increase
to the frontal cortex in rats and mice, respectively (for
of 81 ::!: 0.8 % compared with eticlopride alone (p < 0.001)
review, see Morales and Margolis, 2017). As reductions in
and 115 ::!: 0.8% compared with ACSF (p = 0.002; Fig. 8C,D).
firing were often preceded by acute elevations in activity
Firing frequency did not differ between ACSF and eticlopr(data not shown), it was possible that ghrelin-induced
ide (p = 0.495) .
increases in activity and associated somatodendritic release
Finally, we investigated whether GHS-Rla formation of
could drive a subsequent inhibition of activity in the subset
oligomers with GHS-Rlb and D 1 -like receptors mediated
of dopaminergic neurons more sensitive to D2-autorecepthe observed ghrelin-induced increases in dopaminergic
tor-mediated inhibition. To determine whether ghrelinneuron firing. Baseline recordings were taken, then the
induced reductions in firing observed in a subset of cells
reflects a D2R-dependent pause in firing (Beckstead et al.,
GHS-Rla antagonist JMV2959 or the DlR/D5R antagonist
SCH39166, plus eticlopride, were applied either alone or
2004; Beckstead and Williams, 2007; Ford et al., 2010; Bello
et al., 2011 ; Courtney et al., 2012 ), we applied the D2R antagfollowed by the application of ghrelin. Repeated-measures
AN OVA revealed no differences in firing frequency following the
onist eticlopride before and in combination with ghrelin
(Fig. 8C,D). Bath application of eticlopride alone slightly
application of JMV2959 alone or JMV2959 plus ghrelin compared

-
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probably predominantly mediated by GHS-Rla:
GHS-Rlb:DlR oligomers.

Discussion

The present study supports that GHS-Rla:GHSC"
Q)
Rlb:DlR oligomers are the main mediators of the
it 4
excitatory effects of ghrelin on VTA dopaminergic
C)
.§
cells. We previously showed in mammalian transu:: 2
fected cells and in striatal neurons in culture that
GHS-Rlb facilitates oligomerization of GHS-Rla
ACSF
Ghrelin
ACSF Eticlo. Ghrelin/
Eticio.
with DlR, switching GHS-Rla from its canonical
D
Gq-mediated signaling to a Gs-AC-cAMP signal~4
ing (Navarro et al., 2016). As a biochemical signaN
ACSF
I
ture of the GHS-Rla:GHS-Rlb:DlR oligomer, a
;: 3
0
DlR/DSR antagonist could block ghrelin-induced
C
Q)
cAMP formation in both cell preparations (Navarro
5- 2
et al., 2016). In the present study, the ghrelin~
u.
c
induced increase in the activity of VT A dopaminer=~13ci
u.
gi 1
0
(/)
·;::
gic cells was found both to be dependent on Gs0
..c
·u<(
u::
C> w
ru
AC-cAMP-PKA signaling and counteracted by
00
20
15
25
5
10
DlR/DSR antagonists.
Time (min)
Our initial hypothesis was that DSR should be
the principal D 1-like receptor involved, in view of
E
F 6
its established predominant expression in the mes8
N
N
encephalic dopaminergic cells in the rodent and
~
~
human and nonhuman primates (Ciliax et al., 2000;
>,
i:,6
0
C
Khan
et al., 2000). In fact, the immunohistochemi4
C
Q)
Q)
::::,
::::,
cal
results
by Jiang et al. (2006), showing a signifi00-4
~
~
cant colocalization of GHS-Rla and DlR in the
u.
u. 2
mouse substantia nigra and VTA contradicted the
Cl
Cl
C
.§ 2
·;::
consistently reported lack of DlR mRNA expresu::
u::
sion in the mesencephalic cells of the mammalian
brain (Mansour et al., 1991; Mengod et al., 1991;
ACSF SCH Ghrelin/
ACSF JMV Ghrelin/
SCH
Hurd et al., 2001 ). We fust demonstrated that, simiJMV
larly to DlR, DSR can form oligomers with GHSFigure 8. Activation of VTA dopaminergic cells by ghrelin: electrophysiological experiments. A,
Rla and GHS-Rlb. With resonance energy transfer
eGFP-positive cell in the VTA of an acutely isolated brain slice from a Pitx3 mouse, as visualized via
techniques in mammalian transfected cells, it was
infrared microscopy (top) and epifluorescence (bottom); the dashed circle highlights the cell targeted
possible to show that DSR can form a complex with
for evaluation (pipette visible in the top). 8, Mean firing frequency of dopaminergic neurons in ACSF
GHS-Rla, but only in the presence of GHS-Rlb,
(baseline) and following 5 min bath application of ghrelin using a within -cell approach . (, Mean firing frequency in ACSF and following bath application of the D2R antagonist eticlopride (5 min) and
which alone could also oligomerize with DSR. This
subsequent application of ghrelin and eticlopride. D, Representative trace showing the impact of etistrongly suggests that GHS-Rlb acts as a link
clopride and ghrelin in the presence of eticlopride on firing frequency followed by washout in ACSF;
between DSR and GHS-Rla in the GHS-Rla:GHSlines denote the duration of drug on/off periods, and highlighted boxes denote that the time data
Rlb:DSR complex, in view of the well established
were collected and averaged for firing frequency in ACSF, eticlopride, and ghrelin plus eticlopride. E,
ability of GHS-Rlb to oligomerize with GHS-Rla
Mean firing frequency of dopaminergic neurons in the presence of ACSF, the GHS-Rla antagonist
(see Introduction).
JMV2959, and ghrelin plus JMV2959. F, Mean firing frequency in ACSF and following bath application
Significantly, we could find specific differenof the D1R/D5R antagonist SCH39166 and subsequent application of ghrelin in the presence of
ces in the pharmacological properties of GHSSCH39166. ***p < 0.001 versus ACSF; ##p < 0.01 versus eticlopride alone, repeated-measures
Rla:GHS-Rl b:D lR and GHS-Rla:GHS-Rlb:
ANOVA followed by Tukey's multiple-comparison test.
DSR oligomers. The pharmacological properties
were dependent on the existence of the respective oligomeric complex and could be demonwith ACSF (plus eticlopride; p = 0.83; Fig. SE). Thus, similar to
strated by their dependence on the presence of
LEAP2 in the microdialysis experiments, JMV2959 did not behave
GHS-Rlb. Compared with the GHS-Rla:GHS-Rlb:DlR
as an inverse agonist on dopaminergic cell activity, although it
oligomer, ghrelin promoted a weaker Gs-AC-cAMP signalhas been described as an inverse agonist in some in vitro assays
ing by the GHS-Rla:GHS-Rlb:DSR oligomer. Nevertheless,
(Ramirez et al., 2019). This observation seems to disclose
MAPK signaling was pronounced with both oligomers and
another property of GHS-Rla:GHS-Rlb:DlR oligomers: a
allowed us to disclose a second pharmacological difference.
decrease in the constitutive activity of GHS-Rla. The same as
This is a negative cross talk between ghrelin and a DlR/
for JMV2959, the effect of SCH39166 alone or plus ghrelin did
DSR agonist within the GHS-Rla:GHS-Rlb:DlR oligomer,
not differ from ACSF baseline (plus eticlopride; p =0.07; Fig.
but not the GHS-Rla:GHS-Rlb:DSR oligomer. On the other
SF). Together, these findings indicate that ghrelin augments firing frequency in dopaminergic neurons that are both sensitive
hand, both oligomers showed cross-antagonism with
and insensitive to D2R inhibition and that these actions are
MAPK signaling, with the DlR/DSR antagonist SCH23390
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counteracting ghrelin and the GHS-Rla antagonist YL781
completely counteracting the effect of the DlR/DSR agonist
SKF81297. Cross-antagonism has been repeatedly shown to
be a specific property of GPCR heteromers (Ferre et al.,
2014 ). That the presence of GHS-Rlb induces the ability of
GHS-Rla and DlR/DSR antagonists to respectively crossantagonize D lR/DSR and GHS-Rla agonists, strongly
argues for cross-antagonism between ghrelin and DlR/DSR
ligands as a biochemical property of GHS-Rla:GHS-Rlb:
DlR or GHS-Rla:GHS-Rlb:DSR oligomers. Although there
are no available ligands that can differentiate pharmacologically from DlR and DSR, the present results disclose significant pharmacological differences between both receptors
that depend on their oligomerization with GHS-Rla and
GHS-Rlb. These differences could then be used to identify
the predominant D 1-like receptor subtype forming oligomeric complexes with GHS-Rla and GHS-Rlb, which modulate dopamine function within the VTA. However, it is
important to point out that the evidence for the existence of
GHS-Rl b in the VT A is still correlational and that it needs
still to be demonstrated .
Three different models were used to examine the activating
effects of ghrelin in the VTA, as follows: (1) MAPK activation in
VTA slices; (2) somatodendritic dopamine release in microdialysis experiments; and (3) increased activity of dopaminergic cells
in patch-damp experiments. The most pronounced effect was
the increase of somatodendritic dopamine release in the VTA
and its corresponding projecting area, the NAc, after a slow and
sustained infusion of ghrelin (60 min) into the VTA. On the
other hand, the electrophysiological experiments required D2autoreceptor blockade to disclose the stimulatory effects of
ghrelin. The most likely explanation for this difference is the
reported desensitization of D2-autoreceptors after prolonged
exposure to dopamine, which depends on costimulation of D 1like receptors, probably DSR localized in the VTA dopaminergic cells (Nimitvilai and Brodie, 2010; Nimitvilai et al., 2012a,
b). The dependence on DlR/DSR activation, as well as on the
activation of a Gq/PLC/PKC pathway and calcium signaling,
suggests that a significant population of D2-autoreceptors
could represent D2R-D5R heteromers (Rashid et al., 2007; So et
al., 2009; Nimitvilai et al., 2012a, b). Inhibition of ghrelininduced somatodendritic dopamine release by a DlR/DSR antagonist should therefore involve a reversal of autoreceptor sensitization. Nevertheless, the electrophysiological experiments
demonstrated a clear cross-antagonism with a complete DlR/
DSR antagonist-mediated blockade of ghrelin-induced activation of VT A dopaminergic cells on D2-autoreceptor blockade.
These results implied that oligomers of GHS-Rla, GHS-Rlb,
and D 1-like receptors could represent a main population of
GHS-Rla within the VTA that modulates dopaminergic cell
function .
Unexpectedly, negative cross talk was observed on MAPK
activation in VTA slices induced by ghrelin and the DlR/DSR
agonist SKF81297. In addition, the local perfusion in the VTA of
a PKA inhibitor counteracted ghrelin-induced somatodendritic
dopamine release, disclosing the pharmacological profile of the
GHS-Rla:GHS-Rlb:DlR oligomer. The lack of expression of
DlR in the VTA dopamine neurons would therefore favor a presynaptic localization of the GHS-Rla:GHS-Rlb:DlR oligomer in
VTA glutamatergic or cholinergic excitatory inputs. Indeed, past
work has shown that ghrelin-mediated increases in the fuing frequency of putative VTA dopaminergic neurons are inhibited by
blockade of AMPA- and NMDA-type glutamate receptors and
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align with elevations in the frequency of miniature excitatory
postsynaptic currents- a phenomenon often equated with
increased presynaptic glutamate release (Abizaid et al., 2006).
Our results using patch-damp electrophysiology are also compatible with a presynaptic effect of ghrelin, which may also
explain its nonselective effect on those subsets of dopaminergic
neurons that either do or do not express somatodendritic D2autoreceptors.
There is evidence for a functional role ofpresynaptic D 1-like
receptors localized in glutamatergic terminals in the VTA, which
when activated upon somatodendritic dopamine release promote
glutamate release, and which seem to play an important role in
the pharmacological effects of alcohol and psychostimulants
(Kalivas and Duffy, 1995; Deng et al., 2009; Xiao et al., 2009).
Cholinergic or glutamatergic neurons from the laterodorsal
tegmental area (LDTg) constitute a major excitatory input
to the VTA (Geisler et al., 2007; Watabe-Uchida et al. ,
2012 ), and the LDTg has been shown to express GHS-Rla
mRNA (Guan et al., 1997; Zigman et al., 2006 ). To our
knowledge, there is no evidence for D 1-like receptor expression in the LDTg, but there are other brain areas that also
provide significant glutamatergic inputs to the VTA and
express both GHS-Rla and DlR, which could therefore be
expressed in their VT A nerve terminals. Those include the
paraventricular nucleus of the hypothalamus, the retrorubral field, and the lateral parabrachial nucleus (Thibaut et
al., 1990; Guan et al., 1997; Rivkees and Lachowicz, 1997;
Czyrak et al., 2000; Maltais et al., 2000; Zigman et al., 2006 ;
Geisler et al., 2007; Coizet et al., 2010; Watabe-Uchida et
al., 2012; Mani et al., 2014 ). Experiments are in progress to
determine the possible existence of GHS-Rla:GHS-Rlb:
DlR oligomers in these VTA excitatory inputs, which
should provide a better understanding of the mechanisms
by which GHS-Rla signaling is able to influence the function of VT A dopaminergic neurons.
Apart from the localization of GHS-Rla:GHS-Rlb:DlR
oligomers within the VT A, the origin of the endogenous
ghrelin involved in the functional activation of these receptor complexes needs still to be determined. Some of the proposed mechanisms by which endogenous ghrelin could
activate GHS-Rl in the VTA include its local synthesis, its
peripheral transit to the VT A, and an indirect activation
through circuit-level effects (Cabral et al., 2017; Edwards
and Abizaid, 2017; Perello et al., 2019; Wenthur et al. ,
2019 ). The evidence for central synthesis of ghrelin is modest and hotly debated (Cabral et al., 2017; Edwards and
Abizaid, 2017 ). Nevertheless, we have recently demonstrated that cocaine-mediated reward is sensitive to systemically administered GHS-Rla antagonists, but not to
sequestration of peripheral ghrelin with peripherally acting specific antibodies (Wenthur et al., 2019), which would argue
against the transport of peripheral ghrelin to the CNS as the
primary source of its facilitatory effects on reward-associated
behaviors.
Irrespective of the specific origin of endogenous ghrelin, the
present study strongly suggests that the GHS-Rla:GHS-Rlb:DlR
oligomer localized in the VTA can provide an important pharmacological target for alcohol and psychostimulant use disorders, in view of the preclinical and clinical evidence suggesting
that GHS-Rla antagonists can be useful pharmacological
approaches to treat in these disorders (Jerlhag et al., 2009, 2010;
Zallar et al., 2017; Farokhnia et al., 2019; Wenthur et al., 2019;
Edvardsson et al., 2021 ).
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